2) CA19-9 antigen/serurn
CA-19-9抗原/血清
3) human serum carbohydrate antigen 19-9
血清癌抗原19-9
1.
A novel amperometric immunosensor for human serum carbohydrate antigen 19-9 (CA19-9) based on its antibody (anti CA19-9) coated Fe3O4(core)/Au(shell) gold-magnetic nanocomposites(GMP) modified electrode is investigated.
5磷酸盐缓冲液(PBS)中具有电活性的Au│CS-FeCN电极;再通过外加磁场吸引,在Au│CS-FeCN表面修饰一层血清癌抗原19-9单克隆抗体(antiCA19-9)包被的金磁纳米微粒(Fe3O4(核)/Au(壳),简称GMP),由此构建了一类快速检测CA19-9的无试剂安培免疫传感器(Au│CS-FeCN/GMP-antiCA19-9)。
4) Carbohydrate antigen 19-9
糖类抗原19-9
1.
Objective To explore the clinical values of combining testing gastric juice levels of tumor necrosis factor-α(TNF-α)、carbohydrate antigen 19-9(CA19-9) and carcinoembryonic antigen(CEA) in gastric cancer patients.
目的探讨胃液中肿瘤坏死因子-α(TNF-α)、糖类抗原19-9(CA19-9)和癌胚抗原(CEA)联合检测对胃癌的诊断价值。
5) CA19-9
糖类抗原19-9
1.
Study of serum CA19-9 and bilirubin in obstructive biliary tract diseases
阻塞性胆道疾病患者血清糖类抗原19-9和胆红素的研究
2.
Objective To explore the concentrations and clinical value of CA19-9 in different body fluids such as serum,pancreatic juice,bile,gastric juice and urine in patients with pancreatic cancer and benign biliary pancreatic diseases.
目的:探讨肿瘤标记物糖类抗原19-9(CA19-9)在胰腺癌及胆胰良性疾病患者的多种体液(血清、胰液、胆汁、胃液和尿液)中的表达及其临床意义。
3.
Methods Using tumor markers protein chip, the serum CEA, CA125, CA19-9, NSE and SF levels in 73 cases of non-small cell lung cancer (NSCLC), 21 cases of benign pulmonary disease and 16 cases of normal controls were measured and compared.
目的评价5项血清肿瘤标志物癌胚抗原(CEA)、糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、神经元特异性烯醇化酶(NSE)和铁蛋白(SF)联合检测对提高肺癌临床诊断的价值。
6) Cancer antigen 19 9(CA19 9)
癌糖类抗原19-9
补充资料：非螺旋体抗原血清试验
非螺旋体抗原血清试验
包括性病研究实验室玻片试验(VDRL)、快速血浆反应素试验(RPR)及血清不加热反应素玻片试验(USR)。几种试验均用心磷脂作抗原，检查血清中抗心磷脂抗体。如上述试验阳性，还可作定量试验。用作疗效判断。但在患者有自身免疫病、近期有发热性疾病、妊娠或药瘾时可有假弱阳性反应，确诊需进一步作螺旋体抗原血清试验。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条